

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

NCI-H2087

RRID:CVCL_1524

Type: Cell Line

Proper Citation

RRID:CVCL_1524

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1524

Proper Citation: RRID:CVCL_1524

Description: Cell line NCI-H2087 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:9559342](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:11314036](#), [PMID:11416159](#), [PMID:12068308](#), [PMID:16157194](#), [PMID:16187286](#), [PMID:18397470](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27602502](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2087

Synonyms: H2087, H-2087, NCIH2087

Cross References: BTO:BTO_0003241, CLO:CLO_0008048, EFO:EFO_0002277, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5922, BioGRID_ORCS_Cell_line:533,

BioSample:SAMN03472602, BioSample:SAMN05292451, BioSample:SAMN10987636, cancercellines:CVCL_1524, CCRID:1101HUM-PUMC000253, Cell_Model_Passport:SIDM00708, ChEMBL-Cells:ChEMBL3308770, ChEMBL-Targets:ChEMBL1075532, CLS:305824, Cosmic:724834, Cosmic:877251, Cosmic:877440, Cosmic:903614, Cosmic:917389, Cosmic:961840, Cosmic:980991, Cosmic:1006536, Cosmic:1032463, Cosmic:1146900, Cosmic:1152516, Cosmic:1209730, Cosmic:1219085, Cosmic:1239890, Cosmic:1477422, Cosmic:1518086, Cosmic:1891900, Cosmic:1925847, Cosmic:1995557, Cosmic:2125242, Cosmic-CLP:724834, DepMap:ACH-000841, EGA:EGAS00001000160, EGA:EGAS00001000978, GDSC:724834, GEO:GSM62329, GEO:GSM108835, GEO:GSM108836, GEO:GSM253370, GEO:GSM434306, GEO:GSM513956, GEO:GSM514341, GEO:GSM794350, GEO:GSM817100, GEO:GSM887402, GEO:GSM888481, GEO:GSM1670213, IARC_TP53:513, IGRhCellID:NCIH2087, KCLB:25922, LiGeA:CCLE_912, LINCS_LDP:LCL-1650, Pharmacodb:NCIH2087_1064_2019, PRIDE:PXD030304, Progenetix:CVCL_1524, PubChem_Cell_line:CVCL_1524, Wikidata:Q54907920

ID: CVCL_1524

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260905T181243+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2087.

No alerts have been found for NCI-H2087.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. npj biological physics and mechanics, 2(1), 19.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular cell, 85(7), 1311.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Martin-Vega A, et al. (2024) ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. *Molecular cancer therapeutics*, 23(12), 1789.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Martin-Vega A, et al. (2023) ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers. *bioRxiv : the preprint server for biology*.

Kwon M, et al. (2022) Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. *Cancer research communications*, 2(10), 1197.

Kang YP, et al. (2021) Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis. *Cell metabolism*, 33(1), 174.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Gurtner K, et al. (2020) Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. *International journal of cancer*, 147(2), 472.

Kang YP, et al. (2019) Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. *eLife*, 8.

Mollaoglu G, et al. (2018) The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. *Immunity*, 49(4), 764.

Watanabe H, et al. (2013) Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. *Genes & development*, 27(2), 197.